Eli Lilly's New Weight-Loss Drug Is the Best Yet
This article from Bloomberg may be of interest to subscribers. Here is a section:
Read entire articleRetatrutide’s performance seems to come from its unique way of tinkering with the hormones that control our appetite. Like Wegovy, retatrutide mimics a hormone called GLP-1, which helps to control blood sugar levels by signaling the secretion of insulin after eating. And like tirzepatide, the drug also potently mimics a second hormone involved with insulin secretion called GIP. But retatrutide also stimulates a third hormone, the glucagon receptor, which unlike GLP-1 and GIP is found in the liver — an addition that could be driving some of the drug’s benefits.
Indeed, significant weight loss isn’t the only reason people are excited about the drug’s early data. As I’ve written in the past, obesity medicines still need to prove they can have a positive impact on patients’ health. On that front, Lilly’s drug is already hitting some key metrics. For example, treatment with retatrutide led to a 20% reduction in LDL, or “bad” cholesterol, double the improvement typically seen with other GLP-1 drugs.
And higher doses of retatrutide lowered levels of fat in the liver by over 80%. Liver disease is so common in people with Type 2 diabetes that the American Diabetes Association recently recommended that all Type 2 diabetics be screened for it. And a small portion of people with nonalcoholic fatty liver disease go on to develop a more serious condition called NASH, where accumulation of scar tissue eventually prevents the liver from properly functioning.
The hope is that the right weight-loss drug could tackle obesity, diabetes and liver disease all at once. While larger studies still need to be run, it’s looking a lot like retatrutide might be the one to take on that triple threat.